A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Viatris to Acquire Oyster Point and India-Based Famy Life Sciences for $705 Million
Author: Peter Downs and Jennie Crabbe
Viatris put the ophthalmology business world on notice on Nov. 7 with a major step toward its goal of becoming “the next global ophthalmology leader.” The Pittsburgh company announced a $705 million spend to set up a new ophthalmic business unit through the acquisitions of Oyster Point Pharma and Famy Life Sciences. US-based Oyster Point is the maker of Tyrvaya nasal spray for dry eye. India-based Famy has a pipeline of late-stage candidates for dry eye, blepharitis, and presbyopia. The acqui...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.